TXMD TherapeuticsMD Inc.

2.65
-0.02  -1%
Previous Close 2.67
Open 2.69
Price To Book 88.33
Market Cap 718,472,876
Shares 271,121,840
Volume 2,249,979
Short Ratio
Av. Daily Volume 3,719,981
Stock charts supplied by TradingView

NewsSee all news

  1. TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2019 Healthcare Conference in New York City. Chief Executive Officer Robert

  2. TherapeuticsMD Announces Third Quarter 2019 Financial Results

    - 3Q19 Net Revenue (Product and License) Increased to $23.7 Million - - 3Q19 Product Net Revenue Increased 34% to $8.2 Million Compared to 2Q19- - The Company Reaffirms 4Q19 Financial Guidance - - Conference Call

  3. TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019

    -Executive Management to Host Conference Call on November 6, 2019 at 4:30 p.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that it will report its third quarter

  4. Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

    Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health

  5. Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

    MONTREAL and BOCA RATON, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today that Knight's New Drug

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced October 29, 2018.
TX-001HR: BIJUVA
Moderate to severe vasomotor symptoms (VMS)
CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.
Yuvvexy - TX-004HR
Moderate-to-severe vaginal pain
FDA Approval announced August 10, 2018.
Segesterone Acetate/ Ethinyl Estradiol
Contraception

Latest News

  1. TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2019 Healthcare Conference in New York City. Chief Executive Officer Robert

  2. TherapeuticsMD Announces Third Quarter 2019 Financial Results

    - 3Q19 Net Revenue (Product and License) Increased to $23.7 Million - - 3Q19 Product Net Revenue Increased 34% to $8.2 Million Compared to 2Q19- - The Company Reaffirms 4Q19 Financial Guidance - - Conference Call

  3. TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019

    -Executive Management to Host Conference Call on November 6, 2019 at 4:30 p.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that it will report its third quarter

  4. Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

    Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health

  5. Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada

    MONTREAL and BOCA RATON, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today that Knight's New Drug

  6. TherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock

    TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 29,900,000 shares of its common stock at a price to the public of $2.75 per share, inclusive of the underwriters'

  7. TherapeuticsMD Announces Pricing of Its Underwritten Public Offering of 26 Million Shares of Common Stock

    TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of 26,000,000 shares of its common stock at a price to the public of $2.75 per share. TherapeuticsMD has also granted to

  8. TherapeuticsMD Announces Proposed Underwritten Public Offering of 22 Million Shares of Common Stock

    TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of an underwritten public offering of 22,000,000 shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the offering a 30-day

  9. TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results

    TherapeuticsMD, Inc. (NASDAQ:TXMD) (the "Company") today announced its estimates of the financial results for the third quarter ended September 30, 2019. For the three months ended September 30, 2019, the Company

  10. TherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced the presentation of ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system) findings at the annual meeting of

  11. TherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business

    Jennifer Wilson Recognized as a Finalist for Female Executive of the Year TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that Jennifer Wilson, Vice President of Business

  12. TherapeuticsMD Announces Participation at the 2019 Cantor Healthcare Conference

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York City. Chief Executive Officer

  13. TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society

    TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced the schedule of two oral presentations and five posters that will be presented at the 2019 Annual Meeting of the North